A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth.

By Qianben Wang, Wei Li, X. S. Liu, Jason S. Carroll, O. Jänne, E. Keeton, Arul M. Chinnaiyan, K. Pienta, Myles A. Brown. Molecules and Cells, 2007

683 citations recorded by the source corpus.

Subfields: Genetics, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/a9c26c9d7ba98ac3bc5261f23def82a9ad3c623a

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

In Pulmonary and Respiratory Medicine

Citations in the corpus

An Integrated Network of Androgen Receptor, Polycomb, and TMPRSS2-ERG Gene Fusions in Prostate Cancer Progression (2010, methodology): “Genomic Landscape of AR in Prostate Cancer To determine AR binding sites across the human genome, we performed ChIP-Seq analysis of the LNCaP prostate cancer cells treated with either vehicle or saturating amounts of synthetic androgen R1881 as previously reported (Wang et al., 2007).”
Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. (2007, background): “Moreover, silencing of one transacting factor can negatively affect the reciprocal occupancy of the AR binding sites by another (325).”
Pioneer transcription factors: establishing competence for gene expression. (2011, background): “Mechanistically, AR-binding regions in the androgen-sensitive prostate cancer cell line LnCaP are enriched for Forkhead motifs (Wang et al. 2007; Jia et al. 2008); more than half of the AR-binding events in LnCaP cells overlap with a FoxA1binding event (Lupien et al.”
FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription. (2008, neutral): “Other important candidates for a global role in control of sex steroid signaling through collaborations with FoxA1 and ERa or AR include GATA family members (Eeckhoute et al., 2007; Wang et al., 2007), c-myc (Cheng et al., 2006), and NFIC (Eeckhoute et al., 2006).”
The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis (2011, background): “…important insights into the mechanisms which direct AR signalling (e.g., FOXA1 as an AR pioneer factor) and have identified castrate-resistant disease-specific AR signalling changes (e.g., UBE2C as an AR target only in castrate-resistant prostate cancer) (Wang et al, 2007, 2009; Jia et al, 2008).”
ARN-509: a novel anti-androgen for prostate cancer treatment (2012, positive): “AR was not recruited to the enhancer region of PSA or TMPRSS2 target genes after ARN-509 or MDV3100 treatment under hormonedepleted conditions (Fig.”
Androgen Receptor Regulates a Distinct Transcription Program in Androgen-Independent Prostate Cancer (2009, background): “…AR is expressed in the vast majority of both ADPC and AIPC (Heinlein and Chang, 2004; Scher and Sawyers, 2005) and decreasing levels of AR protein expression reduces both ADPC and AIPC growth in model systems (Chen et al., 2004; Haag et al., 2005; Heinlein and Chang, 2004), it appears AR signaling…”
Nuclear Receptor-Induced Chromosomal Proximity and DNA Breaks Underlie Specific Translocations in Cancer (2009, neutral): “As controls, we observed the binding of AR to PSA promoter and to the recently identified ARE located 13.5 kb upstream of the TMPRSS2 gene (ARE V) (Wang et al., 2007), but no significant binding to either an AR negative binding region in the TMPRSS2 gene (ARE III) ( Wang et al., 2007 ) or the GAPDH ”
Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer (2011, background): “…with the median distance between the respective binding peaks being 43 nt (range, 0–653 nt; Supplementary Figure S2), suggesting a global role of FoxA1 in androgen signalling and providing credence to the pioneering role of FoxA1 in AR binding to chromatin (Wang et al, 2007; Lupien et al, 2008).”